Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD)

20 juin 2021 mis à jour par: Meir Medical Center

Adjustment of Chemotherapy Duration in Follicular Lymphoma Patients According to Peripheral Blood or Bone Marrow Minimal Residual Disease Status

Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events.

Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients even after therapy, and when detected after lymphoma treatment it is referred to as minimal residual disease (MRD).

MRD elimination after effective lymphoma treatment is a marker for deep response and correlates with prolonged remission.

In this study we aim to omit chemotherapy after 4 cycles of treatment in patients achieving MRD elimination after 3 months of therapy, as well as complete metabolic response on positron emission computed tomography (PET-CT), hoping to preserve treatment effectiveness while reducing adverse events.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

Follicular lymphoma (FL) is the second most common type of non-Hodgkin's lymphoma, with an estimated incidence of 3.18 cases per 100000 people a year in the United States The disease is characterized by an indolent behavior, where often treatment is unnecessary at diagnosis, and a "watch & wait" approach is the standard of care for asymptomatic patients. FL is also a highly responsive disease for immuno-chemotherapeutic combinations, although most patients will eventually relapse. Since the disease is incurable & indolent in nature, the therapeutic strategy should aim for disease control, while using treatments with high safety profile in order to minimize the chance for life threatening adverse events.

Therapy with rituximab cyclophosphamide, doxorubicin, vincristine & prednisone (R-CHOP) combination & subsequent rituximab maintenance therapy for 24 months shows excellent results with a median progression free survival (PFS) of above a decade.

The more recent GALLIUM trial has shown that combining the monoclonal antibody obinutuzumab with chemotherapy is even more efficacious compared to rituximab combinations. When different combinations were examined in this trial the best results were achieved with the bendamustine-obinutuzumab (BO) combination with 3 year PFS of 84%. Unfortunately the trial also revealed a downside for this effective combination with higher rate of fatal adverse events among patients receiving 6 cycles of bendamustine combinations.

In patients with acute leukemia evaluation for minimal residual disease (MRD) is a routine procedure, and the nature & length of treatment are guided by MRD status at different time points during therapy.

Among FL patients treated with obinutuzumab-chemotherapy combinations, it has been shown that after 3 cycles of treatment about 90% of patients were MRD negative. In addition MRD negativity at the end of induction in either peripheral blood or bone marrow was found to be associated with improved outcomes in patients with 1st line treatment for FL as well as in the relapsed setting.

These findings raise the possibility for an MRD based treatment approach, where the duration of chemotherapy could be guided by MRD status at mid-induction. Eliminating chemotherapy while continuing immunotherapy after achievement of MRD negativity & complete metabolic remission on PET-CT at mid-induction could reduce treatment toxicity, while potentially preserving efficacy.

Type d'étude

Interventionnel

Inscription (Anticipé)

40

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Kfar Saba, Israël
        • Recrutement
        • Meir Medical Center
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age 18 and above.
  2. FL grade I-IIIa, according to world health organization (WHO) classification, in patients who were not previously treated with chemotherapy, have a high tumor bulk & an indication for treatment, as defined by the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.
  3. Eastern Cooperative Oncology Group (ECOG) performance status grade 0-2.
  4. The presence of a molecular marker in bone marrow or peripheral blood for MRD assessment.

Exclusion Criteria:

  1. FL grade IIIb.
  2. HIV infection.
  3. HBsAg positivity.
  4. Active malignancy other than FL
  5. Pregnancy or lactation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Reduced number of bendamustine cycles in patients with mid-induction MRD negativity
Patients with follicular lymphoma treated with obinutuzumab bendamustine & achieving MRD negativity as well as complete metabolic response on PET-CT at mid-induction would continue obinutuzumab treatment while omitting bendamustin after 4 cycles.
Chemotherapy
Autres noms:
  • Ribomustine
Immunotherapy
Autres noms:
  • Gazyva

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression free survival among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.
Délai: Progression free survival will be assessed 24 months after the end of induction.
Progression-free survival is defined as the time from randomization to the earliest event of progression, relapse, or death from any cause. progression-free survival, is assessed by the investigator.
Progression free survival will be assessed 24 months after the end of induction.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression of disease within 24 months (POD24)
Délai: POD24 will be assessed at 24 months after treatment initiation
POD24 is defined as disease progression or death due to disease progression occurring within 24 months after treatment initiation, as assessed by the investigator.
POD24 will be assessed at 24 months after treatment initiation
Overall survival among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.
Délai: Overall survival will be assessed 24 months after the end of induction.
Overall survival is defined as the time from study initiation to death from any cause.
Overall survival will be assessed 24 months after the end of induction.
The rate of MRD negativity persistence at 12 months among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.
Délai: Persistence of MRD negativity will be assessed 12 months after study initiation.
MRD will be assessed at mid-induction, end of induction and subsequently every 6 months.
Persistence of MRD negativity will be assessed 12 months after study initiation.
The proportion of adverse events among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.
Délai: The proportion of various adverse events will be assessed until 24 months from the end of induction.
The proportion of various adverse events will be assessed as documented by the investigator.
The proportion of various adverse events will be assessed until 24 months from the end of induction.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Uri Abadi, MD, Meir Medical Center

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 janvier 2020

Achèvement primaire (Anticipé)

1 août 2025

Achèvement de l'étude (Anticipé)

1 août 2025

Dates d'inscription aux études

Première soumission

8 avril 2021

Première soumission répondant aux critères de contrôle qualité

20 juin 2021

Première publication (Réel)

22 juin 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 juin 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 juin 2021

Dernière vérification

1 juin 2021

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner